A Phase 2 interventional study of Canadá and Canadá placebo in Pain, Chronic, sponsored by EMS. Withdrawn. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by EMS · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain
2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.
Browse Chronic Pain studies →EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet Canadá, oral; 1 placebo tablet of tramadol, oral; 1 placebo tablet of dipyrone, oral.
Drug: Canadá · Other: Dipyrone placebo · Other: Tramadol hydrochloride placebo
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet tramadol, oral; 1 placebo tablet of Canadá, oral; 1 placebo tablet of dipyrone, oral.
Other: Canadá placebo · Other: Dipyrone placebo · Drug: Tramadol hydrochloride
The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows: 1 tablet dipyrone, oral; 1 placebo tablet of tramadol, oral; 1 placebo tablet of Canadá, oral.
Other: Canadá placebo · Drug: Dipyrone · Other: Tramadol hydrochloride placebo
Canadá association 1 tablet twice a day
Placebo of Canadá association 1 tablet twice a day
Dipyrone 1 tablet twice a day
Placebo of dipyrone 1 tablet twice a day
Tramadol 1 coated tablet twice a day
Placebo of tramadol 1 coated tablet twice a day
Difference in pain intensity assessed by the VAS scale
Change from baseline in the pain intensity escores assessed in medical visits.
Time frame: 12 weeks
Adverse events
Incidence and severity of adverse events recorded during the study
Time frame: 16 weeks
No study locations are listed for this record.
This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EMS